Affiliations 

  • 1 Africa Centers for Disease Control and Prevention, Addis Ababa, Ethiopia. yenewk@africacdc.org
  • 2 African Society for Laboratory Medicine, Addis Ababa, Ethiopia
  • 3 Ministry of Health, Kampala, Uganda
  • 4 Directorate of Biomedical Laboratories, General Directorate of Access to Health Products, Ministry of Health, Ouagadougou, Burkina Faso
  • 5 Eureka Co, Munich, Germany
  • 6 McGill School of Population and Global Health, McGill University, Montreal, Quebec, Canada
  • 7 Africa Centers for Disease Control and Prevention, Addis Ababa, Ethiopia
  • 8 World Health Organization, Geneva, Switzerland
  • 9 Foundation for Innovative New Diagnostics, Geneva, Switzerland
  • 10 Clinton Health Access Initiative, Boston, MA, USA
  • 11 Instituto Nacional de Saúde, Maputo, Mozambique
  • 12 Ministry of Health and Child Care, Harare, Zimbabwe
  • 13 The Global Fund to Fight AIDS, TB and Malaria, Geneva, Switzerland
  • 14 World Health Organization, Africa Office, Brazzaville, Congo
  • 15 International Treatment Preparedness Coalition, Johannesburg, South Africa
  • 16 Gates Foundation, Seattle, WA, USA
  • 17 Unitaid, Geneva, Switzerland
  • 18 Green Templeton College, University of Oxford, Oxford, UK
  • 19 United States Agency for International Development, Washington, DC, USA
  • 20 Stop TB Partnership, Geneva, Switzerland
  • 21 Association of Public Health Laboratories, Silver Spring, MD, USA
  • 22 PATH, Seattle, WA, USA
  • 23 Stephen M Ross School of Business, University of Michigan, Ann Arbor, MI, USA
  • 24 National Health Laboratory, Health Services Management, Ministry of Health and Wellness, Gaborone, Botswana
  • 25 Management Sciences for Health, Center for Pharmaceutical Management, Pretoria, South Africa
  • 26 Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA
  • 27 Boston University Center on Emerging Infectious Diseases, Boston, MA, USA
  • 28 Ministry of Health, Addis Ababa, Ethiopia
  • 29 Namibia Ministry of Health and Social Services, Directorate for Clinical Support Services, Windhoek, Namibia
  • 30 Public Health Authority, Ministry of Health, Victoria, Seychelles
  • 31 Fondation Congolaise pour la Recherche Médicale, Brazzaville, Republic of Congo; Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany
  • 32 Resolve to Save Lives, Abuja, Nigeria
  • 33 Department of Pathology, Aga Khan University, Karachi, Pakistan
  • 34 University of Washington, Seattle, WA, USA
  • 35 Public Health Institute of Malawi, Ministry of Health, Lilongwe, Malawi
  • 36 Laboratoire de Pharmacologie et de Pharmacodynamie, Université Cheikh Anta Diop, Dakar, Sénégal
  • 37 Economic Community of Central African States Commission, Regional Disease Surveillance Systems Enhancement Project, Libreville, Gabon
  • 38 School of Public Health, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda
  • 39 Amref Health Africa Headquarters, Nairobi, Kenya
  • 40 Health Products Policy and Standards Department, World Health Organization, Geneva, Switzerland
  • 41 Department of Pathology, University of Michigan, Ann Arbor, MI, USA
  • 42 University of Chicago, Chicago, IL, USA
  • 43 Ministry of Health, Lusaka, Zambia
  • 44 Directorate of Allied Health, Ministry of Health, Accra, Ghana
  • 45 Medical Laboratory Services Division, Federal Ministry of Health, Abuja, Nigeria
  • 46 Pan-African Treatment Access Movement, Harare, Zimbabwe
  • 47 Matahari Global Solutions, Kuching, Sarawak, Malaysia
  • 48 Médecins Sans Frontières, Southern African Medical Unit, Cape Town, South Africa
  • 49 Department of Digital Health, Stop TB Partnership, Geneva, Switzerland
  • 50 Department of Medical Imaging, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain
  • 51 Direction de la Pharmacie du Medicament et des Laboratoires, Ministerie de la Sante Publique, Yaounde, Cameroon
  • 52 Ministry of Health, Mbabane, Eswatini
Nat Med, 2026 May;32(5):1623-1633.
PMID: 42020602 DOI: 10.1038/s41591-026-04308-7

Abstract

Persistent gaps in access to quality diagnostic tests undermine progress toward improved health outcomes and resilience to disease outbreaks in Africa. Furthermore, resources for strengthening laboratory systems have faced growing constraints owing to recent reductions in official direct financial assistance, highlighting an urgent need to identify investments that are high impact and minimally donor reliant. In this Perspective, we present a set of priority systems strengthening interventions based on expected impact and feasibility. These include the need for efficient and integrated testing networks, the establishment and implementation of national essential diagnostic lists, modernized procurement and supply chain practices, improved digital health standards and targeted strengthening of testing infrastructure for epidemic-prone diseases. These initiatives should be customized to local contexts and supported by reliable financing, enhanced national leadership and management capacity and updated policies. We propose that collective action focused on these priorities will improve health outcomes and be cost-saving-and will be superior to existing, more fragmented efforts to close gaps in testing. This also provides a pathway to self-reliance in health security and universal healthcare in the Africa region.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.